VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2023 | THOR-2 Cohort 3 interim analysis: erdafitinib in intermediate-risk NMIBC with FGFR3/2 alterations

Siamak Daneshmand, MD, University of Southern California, Los Angeles, CA, shares the Cohort 3 interim analysis results of the Phase II THOR-2 (NCT04172675) trial investigating the efficacy and safety of erdafitinib in patients with low-grade intermediate-risk non–muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations. The primary exploratory endpoint was complete response (CR) rate and a key secondary endpoint was safety. All tumors were removed by transurethral resection of bladder tumor except for a marker lesion and cystoscopies were carried out at 6 weeks and 3 months. Of the 8 evaluable patients, 6 had CR and one patient had partial response (PR). The safety data was consistent with the known safety profile of erdafitinib. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter